Knowledge Gaps and Emerging Research Areas in Intrauterine Growth Restriction-Associated Brain Injury

Frontiers in Endocrinology

Bobbi Fleiss¹  Olivier Baud³  Flora Wong⁴  Pierre Gressens⁶  Isabelle K. Shearer⁷  David W. Walker⁷  Mary Tolcos⁷  Fiona Brownfoot⁹ 

[1] Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London, United Kingdom;Department of Paediatrics, Monash University, Clayton, VIC, Australia;Division of Neonatal Intensive Care, University Hospitals of Geneva, Children's Hospital, University of Geneva, Geneva, Switzerland;Monash Newborn, Monash Children's Hospital, Clayton, VIC, Australia;NeuroDiderot, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France;PremUP, Paris, France;School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia;The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia;Translational Obstetrics Group, Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, VIC, Australia;

关键词: growth restriction;    neurobiology and brain physiology;    brain development;    neuroprotection;    neuroinflammation;   

DOI  :  10.3389/fendo.2019.00188

来源: DOAJ

【 摘 要 】

Intrauterine growth restriction (IUGR) is a complex global healthcare issue. Concerted research and clinical efforts have improved our knowledge of the neurodevelopmental sequelae of IUGR which has raised the profile of this complex problem. Nevertheless, there is still a lack of therapies to prevent the substantial rates of fetal demise or the constellation of permanent neurological deficits that arise from IUGR. The purpose of this article is to highlight the clinical and translational gaps in our knowledge that hamper our collective efforts to improve the neurological sequelae of IUGR. Also, we draw attention to cutting-edge tools and techniques that can provide novel insights into this disorder, and technologies that offer the potential for better drug design and delivery. We cover topics including: how we can improve our use of crib-side monitoring options, what we still need to know about inflammation in IUGR, the necessity for more human post-mortem studies, lessons from improved integrated histology-imaging analyses regarding the cell-specific nature of magnetic resonance imaging (MRI) signals, options to improve risk stratification with genomic analysis, and treatments mediated by nanoparticle delivery which are designed to modify specific cell functions.

【 授权许可】

Unknown